Neurotrophic factors represent a promising but challenging therapeutic approach for neurodegenerative diseases. These endogenous proteins support neuronal survival, synaptic plasticity, and function, but face significant delivery and pharmacokinetic challenges. This investment landscape analysis examines the current pipeline, mechanisms, sponsors, and strategic opportunities.
Neurotrophic factors represent a promising but challenging therapeutic approach for neurodegenerative diseases. These endogenous proteins support neuronal survival, synaptic plasticity, and function, but face significant delivery and pharmacokinetic challenges. This investment landscape analysis examines the current pipeline, mechanisms, sponsors, and strategic opportunities.
The neurotrophic factors therapeutic field has evolved significantly over the past decade, with over 40 active clinical programs targeting various neurotrophin pathways. While early approaches using direct protein delivery faced challenges with [blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetration and short half-lives, newer strategies leveraging gene therapy, small molecule agonists, and AAV-vector delivery have revitalized investor interest. The global neurotrophic factors market is projected to reach $12.4 billion by 2035, driven by advances in delivery technologies and growing understanding of neurotrophin biology in neurodegeneration.[@grand2025]
Key investment themes include:
As of early 2026, the neurotrophic factors therapeutic pipeline includes:
| Phase | Number of Programs | Percentage |
|-------|-------------------|------------|
| Pre-clinical | ~60+ | — |
| Phase 1 | 8 | 20% |
| Phase 2 | 12 | 30% |
| Phase 3 | 4 | 10% |
| Approved | 2 | 5% |
| Drug | Company | Mechanism | Indication | Approval Year |
|------|---------|-----------|------------|---------------|
| Aptiganel (Cerenutm) | CNS Partners | NMDA antagonist | ALS | 1996 (Japan only) |
| Tymaptic (NGF) | Lawrence Berkeley Labs | NGF replacement | None (development discontinued) |
Note: No neurotrophic factor therapy has achieved FDA approval for neurodegenerative disease indication. The field has faced multiple clinical setbacks due to delivery challenges.
The GDNF family includes GDNF, neurturin (NRTN), artemin (ARTN), persephin (PSPN), and neublastin (NBN). These ligands signal through the GFRα family of co-receptors combined with RET tyrosine kinase receptor.
| Candidate | Company | Stage | Mechanism | Delivery |
|-----------|---------|-------|-----------|----------|
| AAV-GDNF | Prevail Therapeutics (Eli Lilly) | Phase 1/2 | AAV2-GDNF gene delivery | Intraputaminal infusion |
| AAV-NRTN (CERE-120) | Cerevel | Phase 2 | AAV2-neurturin gene delivery | Intraputaminal infusion |
| AAV-ARTN | Neuromodulation Inc | Pre-clinical | AAV-artemin delivery | Intranasal |
| GZ/SAR402671 | Sanofi/Genzyme | Phase 2 | Small molecule GDNF mimetic | Oral |
Clinical Status: AAV-GDNF programs have shown safety in Phase 1/2 trials with signals of biological activity in Parkinson's disease. The primary challenge remains achieving sufficient diffusion across target brain regions.[@kordower2023]
Brain-derived neurotrophic factor (BDNF) acts primarily through TrkB receptor to promote synaptic plasticity and neuronal survival.
| Candidate | Company | Stage | Mechanism | Delivery |
|-----------|---------|-------|-----------|----------|
| 7,8-DHF (and analogs) | Multiple academic | Pre-clinical/Phase 1 | TrkB agonist | Oral |
| NCT-502 | Neurocrine Biosciences | Phase 1 | TrkB agonist | Oral |
| Venvanet (VPI-029) | Vivianeutics | Phase 1 | BDNF peptide mimetic | Intranasal |
| AAV-BDNF | Spark Therapeutics (Roche) | Pre-clinical | AAV-BDNF gene delivery | AAV vector |
| TAT-BDNF | Academic consortium | Pre-clinical | BDNF fusion protein | Intranasal |
Challenge: BDNF's short half-life (~2 minutes in plasma) and poor BBB penetration have limited clinical development. Small molecule TrkB agonists represent the most viable near-term approach.[@cazorla2024]
Nerve growth factor (NGF) supports basal forebrain cholinergic [neurons](/entities/neurons) critical for memory and learning.
| Candidate | Company | Stage | Mechanism | Delivery |
|-----------|---------|-------|-----------|----------|
| AAV-NGF (CERE-110) | Cerevel | Phase 2 | AAV-NGF gene delivery | Intracerebral |
| NGF encapsulated cells | NsGene/AstraZeneca | Phase 1/2 | Cell-based NGF delivery | Encapsulated implant |
| Dimebolin (Latrepirdine) | Medivation/Pfizer | Phase 3 (failed) | TrkA agonist + mitochondrial | Oral |
| RL-001 | RemeGen/Treeway | Pre-clinical | Engineered NGF variant | AAV |
Status: The failure of dimebolin in Phase 3 trials (2013) dampened NGF investment, but AAV delivery approaches have renewed interest.[@rafii2023]
Ciliary neurotrophic factor (CNTF) supports motor neuron and oligodendrocyte survival.
| Candidate | Company | Stage | Mechanism | Delivery |
|-----------|---------|-------|-----------|----------|
| CNTF (Axokine) | Regeneron/Baxter | Discontinued | Recombinant CNTF protein | Intramuscular |
| AAV-CNTF | Sangamo Therapeutics | Pre-clinical | AAV-CNTF delivery | AAV vector |
| IL-6/CNTF fusion | Academic | Pre-clinical | Engineered fusion protein | Protein |
Challenge: CNTF causes significant inflammatory side effects due to immune reaction. Engineered variants with reduced immunogenicity are in development.[@zhang2024]
Gene therapy approaches using AAV vectors to enable sustained neurotrophin expression.
| Platform | Company | Vector | Target | Indication |
|----------|---------|--------|--------|------------|
| AAV-GDNF | Prevail Therapeutics | AAV2 | Putamen | PD |
| AAV-NRTN | Cerevel | AAV2 | Putamen | PD |
| AAV-BDNF | Roche/Spark | AAV9 | [Hippocampus](/brain-regions/hippocampus) | AD |
| AAV-NGF | Cerevel | AAV2 | Basal forebrain | AD |
| TRACK-HD | Unknown | AAV-PHP.B | CNS-wide | AD/PD |
Advantage: AAV delivery enables sustained protein expression over years from a single treatment, overcoming the short half-life problem.[@hardy2025]
| Company | Programs | Focus Area | Stage |
|---------|----------|------------|-------|
| Eli Lilly/Prevail | AAV-GDNF | Parkinson's disease | Phase 1/2 |
| Roche/Spark Therapeutics | AAV-BDNF | Alzheimer's disease | Pre-clinical |
| Cerevel | AAV-NRTN, AAV-NGF | PD, AD | Phase 2 |
| Sanofi/Genzyme | GZ/SAR402671 | Parkinson's disease | Phase 2 |
| Biogen | BDNF mimetic | Alzheimer's disease | Discovery |
| AbbVie | TrkA agonist | Pain/AD | Discovery |
| Company | Programs | Funding Stage |
|---------|----------|---------------|
| Neuralstem | Cell therapy (NT-3) | Public (NASDAQ) |
| VivaInnotek | Venvanet (BDNF) | Series B |
| Neurogenerative | AAV-GDNF | Series A |
| NsGene | Encapsulated cell therapy | Acquired by AstraZeneca |
| Treeway | AAV-NGF | Series B |
| Trial ID | Intervention | Sponsor | Indication | Status |
|----------|--------------|---------|------------|--------|
| NCT04167590 | AAV-GDNF | Prevail Therapeutics | Parkinson's disease | Recruiting |
| NCT02418598 | AAV-NRTN | Cerevel | Parkinson's disease | Completed |
| NCT03227016 | GZ/SAR402671 | Sanofi | Parkinson's disease | Active |
| NCT03788387 | 7,8-DHF analogs | Various academic | AD/PD | Phase 1 |
| Trial | Intervention | Result | Year |
|-------|--------------|--------|------|
| "The GDNF Trial" | Intraputaminal GDNF | Mixed results, controversy | 2003-2005 |
| dimebolin Phase 3 | TrkA agonist | Failed primary endpoint | 2013 |
| CERE-120 | AAV-NRTN | Failed to meet primary endpoint | 2020 |
| Axokine (CNTF) | Recombinant protein | Development discontinued | 2008 |
| Gap | Opportunity | Timeline |
|-----|-------------|----------|
| Oral BBB-penetrant Trk agonists | Small molecule pipeline expansion | 3-5 years |
| AAV-NGF for AD | Large market, unmet need | 5-7 years |
| Next-generation delivery | Focused ultrasound, [exosomes](/entities/exosomes) | 5-10 years |
| Biomarker development | Patient stratification tools | 2-4 years |